Targeting G-Quadruplex DNA for Cancer Chemotherapy
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
The self-association of DNA formed by Hoogsteen hydrogen bonding comprises several layers of four guanine or G-tetrads or G4s. The distinct feature of G4s, such as the G-tetrads and loops, qualify structure-selective recognition by small molecules and various ligands and can act as potential anticancer therapeutic molecules. The G4 selective ligands can influence gene expression by targeting a nucleic acid structure rather than sequence. Telomere G4 can be targeted for cancer treatment by small molecules inhibiting the telomerase activity, whereas c-MYC is capable of controlling transcription and can be targeted to influence transcription. The k-RAS is one of the most frequently encountered oncogenic driver mutations in pancreatic, colorectal, and lung cancers. The k-RAS oncogene plays an important role in acquiring and increasing drug resistance and can also be directly targeted by small molecules to combat k-RAS mutant tumors. Modular G4 ligands with different functional groups, side chains, and rotatable bonds, as well as conformation, affect the binding affinity/ selectivity in cancer chemotherapeutic interventions. These modular G4 ligands act by targeting the diversity of G4 loops and groves and assist in developing more drug-like compounds with selectivity. In this review, we present the recent research on synthetic G4 DNA-interacting ligands as an approach towards the discovery of target-specific anticancer chemotherapeutic agents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Current drug discovery technologies - 19(2022), 3 vom: 12., Seite e140222201110 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Debbarma, Sumanta [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9007-49-2 |
|---|
| Anmerkungen: |
Date Completed 25.05.2022 Date Revised 27.10.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1570163819666220214115408 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336886985 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336886985 | ||
| 003 | DE-627 | ||
| 005 | 20231225233149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1570163819666220214115408 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1122.xml |
| 035 | |a (DE-627)NLM336886985 | ||
| 035 | |a (NLM)35156574 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Debbarma, Sumanta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting G-Quadruplex DNA for Cancer Chemotherapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.05.2022 | ||
| 500 | |a Date Revised 27.10.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a The self-association of DNA formed by Hoogsteen hydrogen bonding comprises several layers of four guanine or G-tetrads or G4s. The distinct feature of G4s, such as the G-tetrads and loops, qualify structure-selective recognition by small molecules and various ligands and can act as potential anticancer therapeutic molecules. The G4 selective ligands can influence gene expression by targeting a nucleic acid structure rather than sequence. Telomere G4 can be targeted for cancer treatment by small molecules inhibiting the telomerase activity, whereas c-MYC is capable of controlling transcription and can be targeted to influence transcription. The k-RAS is one of the most frequently encountered oncogenic driver mutations in pancreatic, colorectal, and lung cancers. The k-RAS oncogene plays an important role in acquiring and increasing drug resistance and can also be directly targeted by small molecules to combat k-RAS mutant tumors. Modular G4 ligands with different functional groups, side chains, and rotatable bonds, as well as conformation, affect the binding affinity/ selectivity in cancer chemotherapeutic interventions. These modular G4 ligands act by targeting the diversity of G4 loops and groves and assist in developing more drug-like compounds with selectivity. In this review, we present the recent research on synthetic G4 DNA-interacting ligands as an approach towards the discovery of target-specific anticancer chemotherapeutic agents | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a G-Quadruplex | |
| 650 | 4 | |a anticancer G4 ligands | |
| 650 | 4 | |a c-MYC | |
| 650 | 4 | |a k-RAS | |
| 650 | 4 | |a modular G4 ligand | |
| 650 | 4 | |a telomerase inhibitors | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a DNA |2 NLM | |
| 650 | 7 | |a 9007-49-2 |2 NLM | |
| 700 | 1 | |a Acharya, Pratap Chandra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug discovery technologies |d 2004 |g 19(2022), 3 vom: 12., Seite e140222201110 |w (DE-627)NLM160661455 |x 1875-6220 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2022 |g number:3 |g day:12 |g pages:e140222201110 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1570163819666220214115408 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2022 |e 3 |b 12 |h e140222201110 | ||